107 related articles for article (PubMed ID: 16765943)
1. (R)-roscovitine (CYC202, Seliciclib) sensitizes SH-SY5Y neuroblastoma cells to nutlin-3-induced apoptosis.
Ribas J; Boix J; Meijer L
Exp Cell Res; 2006 Jul; 312(12):2394-400. PubMed ID: 16765943
[TBL] [Abstract][Full Text] [Related]
2. Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.
Cheok CF; Dey A; Lane DP
Mol Cancer Res; 2007 Nov; 5(11):1133-45. PubMed ID: 18025259
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional modulation of apoptosis regulators by roscovitine and related compounds.
Garrofé-Ochoa X; Cosialls AM; Ribas J; Gil J; Boix J
Apoptosis; 2011 Jul; 16(7):660-70. PubMed ID: 21505869
[TBL] [Abstract][Full Text] [Related]
5. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells.
Secchiero P; Zerbinati C; di Iasio MG; Melloni E; Tiribelli M; Grill V; Zauli G
Curr Drug Metab; 2007 May; 8(4):395-403. PubMed ID: 17504227
[TBL] [Abstract][Full Text] [Related]
6. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours.
Bauer S; Mühlenberg T; Leahy M; Hoiczyk M; Gauler T; Schuler M; Looijenga L
Eur Urol; 2010 Apr; 57(4):679-87. PubMed ID: 19560254
[TBL] [Abstract][Full Text] [Related]
8. Cell differentiation, caspase inhibition, and macromolecular synthesis blockage, but not BCL-2 or BCL-XL proteins, protect SH-SY5Y cells from apoptosis triggered by two CDK inhibitory drugs.
Ribas J; Boix J
Exp Cell Res; 2004 Apr; 295(1):9-24. PubMed ID: 15051486
[TBL] [Abstract][Full Text] [Related]
9. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
10. Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumors.
Vaseva AV; Yallowitz AR; Marchenko ND; Xu S; Moll UM
Cell Death Dis; 2011 May; 2(5):e156. PubMed ID: 21562588
[TBL] [Abstract][Full Text] [Related]
11. The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73.
Peirce SK; Findley HW
Int J Oncol; 2009 May; 34(5):1395-402. PubMed ID: 19360352
[TBL] [Abstract][Full Text] [Related]
12. Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3.
Michaelis M; Rothweiler F; Klassert D; von Deimling A; Weber K; Fehse B; Kammerer B; Doerr HW; Cinatl J
Cancer Res; 2009 Jan; 69(2):416-21. PubMed ID: 19147553
[TBL] [Abstract][Full Text] [Related]
13. Oridonin synergizes with Nutlin-3 in osteosarcoma cells by modulating the levels of multiple Bcl-2 family proteins.
Wang XH; Zhang SF; Bao JT; Liu FY
Tumour Biol; 2017 Jun; 39(6):1010428317701638. PubMed ID: 28618955
[TBL] [Abstract][Full Text] [Related]
14. MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death.
Barbieri E; Mehta P; Chen Z; Zhang L; Slack A; Berg S; Shohet JM
Mol Cancer Ther; 2006 Sep; 5(9):2358-65. PubMed ID: 16985070
[TBL] [Abstract][Full Text] [Related]
15. Caspase 8/10 are not mediating apoptosis in neuroblastoma cells treated with CDK inhibitory drugs.
Ribas J; Gomez-Arbones X; Boix J
Eur J Pharmacol; 2005 Nov; 524(1-3):49-52. PubMed ID: 16243312
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ
Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546
[TBL] [Abstract][Full Text] [Related]
17. Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen.
Michaelis M; Agha B; Rothweiler F; Löschmann N; Voges Y; Mittelbronn M; Starzetz T; Harter PN; Abhari BA; Fulda S; Westermann F; Riecken K; Spek S; Langer K; Wiese M; Dirks WG; Zehner R; Cinatl J; Wass MN; Cinatl J
Sci Rep; 2015 Feb; 5():8202. PubMed ID: 25644037
[TBL] [Abstract][Full Text] [Related]
18. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases.
Bettayeb K; Oumata N; Echalier A; Ferandin Y; Endicott JA; Galons H; Meijer L
Oncogene; 2008 Oct; 27(44):5797-807. PubMed ID: 18574471
[TBL] [Abstract][Full Text] [Related]
19. Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas.
Crane EK; Kwan SY; Izaguirre DI; Tsang YT; Mullany LK; Zu Z; Richards JS; Gershenson DM; Wong KK
PLoS One; 2015; 10(8):e0135101. PubMed ID: 26248031
[TBL] [Abstract][Full Text] [Related]
20. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma.
Raje N; Kumar S; Hideshima T; Roccaro A; Ishitsuka K; Yasui H; Shiraishi N; Chauhan D; Munshi NC; Green SR; Anderson KC
Blood; 2005 Aug; 106(3):1042-7. PubMed ID: 15827128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
